On March 26th, MPLN’s Chief Scientific Officer and Director of Molecular Diagnostics, Dr. Nicholas Potter, appeared before the FDA Molecular and Clinical Genetics Advisory Committee to offer commentary on behalf of a new colorectal cancer screening test. The Epi proColon® test from Epigenomics, a blood based PCR test for the detection of methylated septin 9 in plasma, received a favorable vote from the Committee, indicating that the benefits of the proposed test outweigh the risks. The Advisory Committee meeting was part of Epigenomics PMA submission to the FDA for approval of Epi proColon. Epigenomics hopes to offer the test as an alternative for people unable or unwilling to avail themselves of existing colon cancer screening methods.
No comments yet. Be the first to leave a comment below.